MedTrace Logo

Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients

NCT04018261 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2024-01-24

No results posted yet for this study

Summary

Marrow transplanted immunocompromised patients with cytomegalovirus (CMV) viral infection will be treated with CMV activated T-Lymphocytes. T-Lymphocytes will be obtained through an apheresis from a compatible donor.

Safety and immunoreconstitution parameters in blood samples will be assessed up to +60 days after the treatment.

Conditions

  • CMV Viremia
  • Immunosuppression-related Infectious Disease

Interventions

DRUG

Activated T-Lymphocytes

Activated T-Lymphocytes will be infused intravenously in a single-dose

Sponsors & Collaborators

  • Vall d'Hebron Institute of Oncology

    collaborator OTHER

  • Hospital Universitario La Fe

    collaborator OTHER

  • Banc de Sang i Teixits

    lead OTHER

Principal Investigators

  • Pere Barba, MD, PhD · VHIO (Vall d'Hebron Institute of Oncology)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-04
Primary Completion
2021-10-18
Completion
2021-10-18

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04018261 on ClinicalTrials.gov